Biotech Tweet of the Week: Love Being Private

This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public companies are required to release information that's material to their stock price.

While it's easy to ignore this nuance since most investors can't invest in private companies, that's not a wise move. As Fool contributor Brian Orelli and health-care bureau chief Max Macaluso point out in the video below, private companies can have drugs that compete with the public companies you're invested in.

Privately held Boehringer Ingelheim, for instance, has an idiopathic pulmonary fibrosis drug that will compete with InterMune's (NASDAQ: ITMN  ) Esbriet if it's approved. Investors will have to wait for the full data at American Thoracic Society in May to see how much of a threat Boehringer Ingelheim's nintedanib will be to InterMune.

And the three public obesity drug makers Arena Pharmaceuticals (NASDAQ: ARNA  ) , VIVUS (NASDAQ: VVUS  ) , and Orexigen (NASDAQ: OREX  ) might be most focused on each other, but investors should keep an eye on Zafgen, which has a drug called beloranib in phase 2 trials. Zafgen is testing beloranib in patients with a severe form of genetic obesity called Prader-Willi syndrome, but if it works well there, it could be a competitor to Arena's Belviq, VIVUS' Qsymia, and Orexigen's Contrave.

Watch the video below for more information about the competition and how big pharma, such as Pfizer (NYSE: PFE  ) , can use its large size to hold back data as well.

These three stocks are public
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 14, 2014, at 9:00 PM, Paulson545 wrote:

    ERBA Diagnostics ( erb ) just reported blow out earnings.

  • Report this Comment On April 17, 2014, at 3:42 AM, marp11 wrote:

    trust me osmelli,,,ARNA /EISAI doesnt give a rats ass about Q or Contrave,,,,

    ps like our TV ads?? quite good.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2914955, ~/Articles/ArticleHandler.aspx, 8/21/2014 3:06:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement